Blog
August 9, 2026
Dry AMD is frequently described as the “mild” form of macular degeneration. That shorthand can mislead. Early and intermediate nonexudative AMD often cause little functional loss, but geographic atrophy is a late, irreversible form that can profoundly affect central vision. At the same time, an early drusen finding does not mean that GA is inevitable.
Understanding progression requires more than a list of stages. Patients need to know what drusen represent, why deposits sometimes disappear before vision worsens, how atrophy can spare the exact center while disrupting reading and what current treatments can and cannot accomplish.
This article follows that biological and clinical pathway without repeating Netra Eye Institute’s general AMD landing page. It emphasizes change over time, structure–function differences and the decisions that arise as dry AMD advances.
Nonexudative, nonneovascular and dry AMD are overlapping terms used when the eye does not show active leakage or bleeding from macular neovascularization. They encompass early and intermediate disease as well as GA. “Dry” describes absence of exudation; it does not mean that the retina lacks normal fluid or that dehydration caused the condition.
An eye can have nonexudative findings today and develop neovascular AMD later. An eye with established GA can also develop a leaking neovascular lesion. Conversely, anti-VEGF treatment can control leakage while scar or atrophy remains. The dry–wet distinction is therefore a current phenotype, not two completely separate lifelong diseases.
Photoreceptors capture light and depend on the retinal pigment epithelium (RPE) for visual-cycle support, outer-segment renewal, transport and barrier functions. Bruch’s membrane separates the RPE from the choriocapillaris, which supplies the outer retina. All three layers participate in AMD.
With age and inherited susceptibility, lipids and extracellular material accumulate, transport changes and oxidative and immune-complement pathways can become dysregulated. Choriocapillaris perfusion and RPE function may decline. Deposits form below or above the RPE, photoreceptor-associated bands become abnormal and local atrophy can emerge.
This is an interacting tissue ecosystem. Calling AMD only a circulation problem, only inflammation or only oxidative stress turns one pathway into the entire disease. That simplification fuels unsupported “blood-flow boosters,” detoxes and antioxidant megadoses.
Conventional drusen are extracellular deposits located between the RPE basal lamina and the inner collagenous layer of Bruch’s membrane. On examination they appear yellow-white. Their composition includes lipids, proteins, complement components and other material.
Small hard drusen are common with aging and do not automatically represent clinically meaningful AMD. Intermediate and large soft drusen, especially when numerous or confluent and accompanied by pigment change, are more characteristic of AMD and raise progression concern.
Subretinal drusenoid deposits—often called reticular pseudodrusen—lie above the RPE in the subretinal space. They have a different appearance and associations, including greater risk of atrophy in many cohorts. Multimodal imaging is often needed because color photographs alone can miss them.
Patients cannot judge drusen burden from symptoms. Deposits are measured by examination, photography and OCT. A report should state size, distribution, associated pigment change and stage rather than simply “some drusen.”
Drusen indicate an altered RPE–Bruch’s membrane environment, but one deposit does not reveal its future. Some remain stable, some grow or coalesce, and some regress. Risk depends on both eyes, lesion characteristics and time.
Drusen do not mechanically block vision like dirt on a window. Attempts to dissolve or massage them away lack clinical evidence and could delay monitoring. Even if a product changed the visible deposit, the surrounding photoreceptor, RPE, choriocapillaris and complement biology would still determine outcome.
The size of the largest druse, total area and pigment abnormalities helped define traditional progression scales. OCT now adds internal features that can refine risk. These estimates describe populations rather than an exact personal schedule.
Common classification systems define early AMD by medium-sized drusen without the more extensive changes of intermediate disease. Many people have no symptoms and maintain excellent acuity. Diagnosis is often incidental during a dilated examination.
Early AMD generally does not justify AREDS2 solely on stage. It does justify a clear follow-up interval, smoking avoidance and attention to systemic health. The clinician must also distinguish ordinary small age-related deposits from AMD and from inherited or pattern dystrophies.
“Early” refers to retinal stage, not necessarily the patient’s age or the time since disease truly began. A newly diagnosed person may have had stable deposits for years.
Intermediate disease includes large drusen or extensive smaller deposits and/or pigment abnormalities, depending on the classification used. Some people remain asymptomatic; others notice more light is needed, slower dark adaptation, reduced contrast or mild central blur.
At this stage, progression risk becomes more clinically relevant. AREDS2 eligibility is commonly considered, and home monitoring for new distortion may be recommended. Serial OCT can identify features associated with later GA or neovascular conversion.
Intermediate AMD is not synonymous with inevitable late disease. It is a reason for structured surveillance. Follow-up depends on the fellow eye, OCT findings, symptoms and clinician judgment.
Hyperpigmentation or depigmentation on color photography reflects altered RPE and pigment distribution. On OCT, intraretinal hyperreflective foci may represent migrated RPE-related cells or other material. These features have been associated with progression in cohort studies.
Pigment terminology can sound cosmetic, but the RPE is essential support tissue. Change in its distribution may signal stress beyond a druse itself. Still, one spot should not be used to predict a date of vision loss.
When large confluent drusen elevate the RPE over a broader area, clinicians may use the term drusenoid pigment epithelial detachment (PED). OCT shows a smooth or irregular elevation with material beneath the RPE.
Drusenoid PED can remain stable, collapse toward atrophy or develop neovascular complications. Its behavior differs from a serous or fibrovascular PED. The word “detachment” can alarm patients, but it does not mean the same thing as a retinal detachment in the periphery and does not call for emergency surgery by itself.
Patients sometimes celebrate when a follow-up photograph shows fewer deposits. Drusen regression can occur as the overlying RPE and photoreceptor tissue deteriorate. A collapsing drusenoid PED may be followed by an area of atrophy.
The proper question is not “Are there fewer yellow spots?” but “What happened to the outer retinal layers and RPE?” OCT, autofluorescence and examination answer that. Stable resolution without atrophy and regression associated with tissue loss are biologically different.
This explains why an unvalidated remedy cannot claim success from a photograph showing smaller drusen. Functional outcomes and tissue integrity matter.
Consensus OCT terminology recognizes stages before fully developed geographic atrophy. Incomplete RPE and outer retinal atrophy may show localized photoreceptor loss, RPE attenuation or disruption and increased transmission of light into the choroid without meeting all criteria for complete atrophy.
Other risk-associated features include hyperreflective foci, hyporeflective drusen cores, abnormalities of the external limiting membrane or ellipsoid zone, subretinal drusenoid deposits and drusenoid PED. A 2024 systematic review found varying strengths and certainty across biomarkers.
These observations support closer surveillance but are not independently treatable lesions in routine care. Automated segmentation can fail near irregular RPE, so clinicians inspect the actual B-scans.
GA is a late-stage AMD phenotype characterized by well-demarcated loss of RPE and overlying photoreceptors with involvement of the choriocapillaris. On ophthalmoscopy, deeper choroidal vessels may become visible through the atrophic area. FAF often shows reduced signal, while OCT documents outer retinal and RPE loss.
The term “geographic” refers to the map-like outline, not geography or where someone lives. Lesions may be single or multifocal, circular or irregular. They usually enlarge over time, but rate varies substantially among people and between eyes.
Atrophy due to AMD must be distinguished from Stargardt disease, pattern dystrophy, medication toxicity, pathologic myopia, inflammation and other causes. Age and appearance alone are not enough when the pattern is unusual.
GA often begins outside the exact foveal center. A small central island can preserve the ability to identify high-contrast chart letters. This “foveal sparing” may make acuity look reassuring even as surrounding atrophy fragments text and slows reading.
The patient may lose place, miss letters, need brighter light or struggle to recognize faces quickly. Contrast sensitivity and low-luminance performance decline. Microperimetry can map retinal sensitivity and fixation behavior more directly than acuity.
Once atrophy reaches the foveal center, acuity may fall more noticeably. The timing is not predicted by total lesion area alone; location, shape and direction of growth matter.
There is no universal speed. A 2025 meta-analysis across imaging studies estimated average area growth around 1.5 to 1.8 square millimeters per year for AMD-related GA, depending on modality, with wide variation. Larger baseline lesions often gain more absolute area per year simply because they have longer borders.
Square-millimeter growth can be misleading when comparing lesions of different starting sizes. Researchers sometimes transform area to an effective radius to reduce size dependence. Clinical reports may use area, linear dimensions or images overlaid across visits.
Multifocal, nonfoveal lesions and certain autofluorescence patterns have often been associated with faster enlargement, while genetic and behavioral associations are more complex. Prior growth in the same eye can inform future expectation, but it remains an estimate.
Patients should be told the time interval and measurement uncertainty. A tiny apparent annual change may reflect segmentation or image-registration differences; a consistent border shift across serial images is more convincing.
GA does not protect an eye from neovascular AMD. New vessels can arise at or away from atrophic borders and leak fluid or blood. Complement-inhibitor trials also observed increased rates of neovascular AMD in treated eyes, making monitoring important.
New distortion, a sudden central smudge, hemorrhage or new OCT fluid requires prompt retina evaluation. Do not assume gradual dry disease explains an abrupt change. Anti-VEGF treatment can control neovascular activity even while atrophy continues to affect other areas.
An eye previously treated for wet AMD may develop macular atrophy from the underlying disease, scar, treatment-era factors or their interaction. It is too simplistic to attribute every atrophic change to injections or, conversely, to deny that longitudinal anatomy is complex. Treatment prevents the far more immediate damage of uncontrolled exudation.
Dilated examination identifies drusen, pigment, hemorrhage and atrophy. Color photographs document visible change. OCT shows drusen architecture, fluid, photoreceptor bands and RPE loss. FAF outlines atrophic patterns and borders. OCTA or dye angiography is used when neovascularization is suspected.
The clinician interprets both eyes and compares prior studies. An image report should translate into a stage, expected follow-up and action plan. Read Inside an AMD Evaluation when that companion draft is available.
Functional monitoring can include acuity, reading performance, contrast, low-luminance measures, microperimetry and patient-reported tasks. Structure and function do not change in perfect synchrony.
Classification systems were built for different purposes. The Beckman clinical scale uses drusen size and pigment abnormalities to group normal aging, early, intermediate and late AMD. AREDS severity scales offer more detailed research-based risk estimates. OCT consensus terms describe atrophic tissue in layers. Billing codes divide nonexudative AMD by stage and laterality.
These systems overlap but are not identical. A portal code saying “advanced atrophic nonexudative AMD, subfoveal involvement” conveys different information from “intermediate dry AMD.” The report should identify each eye separately because stage and treatment history may differ.
“Late” does not necessarily mean total central blindness. Nonfoveal GA is late by anatomy while foveal acuity can be preserved. “Dry” does not mean stable. “Inactive wet AMD” refers to controlled neovascular disease, not the absence of prior tissue damage. Asking the clinician to translate the label prevents unnecessary alarm and false reassurance.
High-contrast acuity tests whether a small central target can be resolved under favorable conditions. GA can disrupt a ring around that target, forcing the eye to jump across missing letters during continuous reading. A person may read a single 20/30 letter yet be unable to sustain a paragraph.
Contrast sensitivity measures performance when letters or objects blend with their background. Low-luminance acuity challenges vision under dimmer conditions. Reading tests capture speed and errors. Microperimetry presents stimuli at known retinal locations while tracking fixation, producing a sensitivity map across and around the lesion.
Patient-reported outcomes add what laboratory tests miss: recognizing a grandchild in a restaurant, finding food on a plate, reading a thermostat or adapting after bright sunlight. These reports are not “subjective noise.” When collected consistently, they explain the lived consequences of lesion location.
Function also depends on the two eyes together. A better eye can mask early loss; mismatched image quality or scotomas can create binocular interference. Cataract, dry eye, glaucoma, hearing, cognition and hand dexterity influence task performance and rehabilitation choices.
The decision is not simply treatment versus doing nothing. Observation includes scheduled imaging, AREDS2 review, symptom instructions, risk-factor care and rehabilitation. Injection therapy adds repeated procedures intended to slow average anatomical enlargement.
Ask the retina specialist to show the lesion border and fovea, explain the observed or expected growth direction and quantify benefit in absolute as well as relative terms. Trial averages may not predict an individual eye. Ask whether evidence applies to a foveal or nonfoveal lesion like yours and whether both eyes should be treated.
Burden is part of effectiveness. Transportation, caregiver time, copayments, antiseptic irritation and the ability to report post-injection symptoms influence whether a schedule is sustainable. The fellow eye’s acuity and disease can change priorities. A person may reasonably choose differently as anatomy or life circumstances change.
Safety monitoring includes looking for conversion to neovascular AMD, inflammation, infection, pressure elevation and retinal tear or detachment. Product labeling and postmarketing safety information can evolve. A decision made last year should be revisited as the lesion, evidence and patient goals change.
Slowing lesion growth is meaningful when it preserves useful retinal area longer, but it is not the same as improving today’s vision. Rehabilitation should proceed alongside medical care rather than being postponed in hope that an injection will restore lost tissue.
Progressive central loss can bring grief, fear of dependency and withdrawal from reading or social contact. Depression is not an inevitable reaction, but it is common enough to screen for. Statements such as “nothing can be done” are inaccurate even when lost retina cannot be restored.
Medical treatment may slow anatomy; low-vision care, NRT, occupational therapy and accessibility can improve task performance; mobility and home changes can reduce risk; counseling and peer support can address adjustment. Early planning preserves choices.
Create a practical record of retinal diagnoses, medications, injection contacts and transportation options. Learn device accessibility before a crisis. Add contrast to steps, organize medication and discuss driving changes before a collision. These actions are adaptations to a changing input, not evidence of giving up.
Family members can help without taking over. Ask which tasks are difficult, preserve the person’s preferred organization and offer guided assistance instead of moving objects unexpectedly. Independence often improves when the environment becomes predictable.
The AREDS2 formulation contains vitamin C, vitamin E, zinc, copper, lutein and zeaxanthin in studied doses. It reduces progression to advanced AMD for eligible patients, especially those with intermediate disease or late AMD in one eye. It is not a universal prevention vitamin.
A 2024 NEI reanalysis suggested that among participants who developed GA away from the fovea, AREDS/AREDS2 supplementation slowed progression toward the foveal center by about 55% over an average of three years. This was a post hoc analysis of trial imaging, and NEI noted plans for confirmatory study. It supports continued clinician-directed use in late dry AMD but should not be presented as tissue restoration.
Patients should use a verified AREDS2 label, avoid beta-carotene formulas if they smoke or formerly smoked and review medication and medical history. More than the tested dose is not better. Supplements do not replace injections if neovascular disease develops.
The FDA approved pegcetacoplan (SYFOVRE), targeting complement C3, and avacincaptad pegol (IZERVAY), targeting complement C5, for GA secondary to AMD. Both are intravitreal injections. Trials measured slowing of lesion-area growth compared with sham; they did not demonstrate regeneration of atrophic retina.
The average anatomical effect must be translated into an individual decision. Factors include lesion location and growth, vision in both eyes, age, ability to attend repeated injections, treatment interval, goals, cost and tolerance for risk. Potential harms include endophthalmitis, inflammation, retinal tear or detachment, pressure changes and increased neovascular AMD risk; product-specific labeling and safety updates matter.
An imaging benefit may not produce a noticeable short-term acuity change, especially with foveal sparing. Conversely, a person with very advanced central atrophy may judge injection burden differently. Shared decision-making should state the likely magnitude and uncertainty rather than promise “vision preservation” without context.
Treatment does not eliminate the need for home symptom awareness, AREDS2 assessment, smoking cessation or rehabilitation. Patients should follow the retina specialist’s schedule and report pain, redness or decreased vision after injection urgently.
When treatment is started, define success before the first injection. Because the expected effect is slower enlargement rather than visible improvement, day-to-day acuity is a poor scorecard. The clinician follows registered OCT or autofluorescence images over meaningful intervals and watches for complications. A lesion can still grow during effective therapy; the relevant comparison is the estimated untreated trajectory, which cannot be observed directly in the same eye. This uncertainty should be acknowledged rather than interpreted as treatment failure or proof of success from one image.
If treatment is paused or stopped, document why and what surveillance continues. The choice should be revisited if the fellow eye changes, new safety information appears or practical barriers can be reduced.
Research includes complement modulation, neuroprotection, visual-cycle approaches, cell-based strategies, gene delivery and devices. A plausible mechanism or early-phase safety study is not proof of clinical benefit. Trial endpoints may be lesion growth, sensitivity or safety rather than restored reading vision.
Unapproved stem-cell injections, exosome products, “retinal regeneration” drops, red-light packages and intravenous vitamin protocols can be expensive and harmful. Ask whether a product has FDA approval for GA, whether evidence comes from randomized peer-reviewed trials and whether adverse events were reported.
Clinical-trial participation should use a registered protocol, informed consent, oversight and a clear statement of costs. Paying a large fee for an experimental injection is a warning sign, not evidence of innovation.
Stopping smoking remains the most important modifiable action. Blood pressure, diabetes and cardiovascular disease should be managed for established systemic benefit. A varied dietary pattern rich in vegetables, legumes, whole grains and fish is more defensible than restrictive “macular detox” plans.
Ordinary reading and screen use do not wear out remaining photoreceptors. Continue meaningful visual activity with appropriate lighting, enlargement and breaks. UV-blocking eyewear is sensible broad ocular protection; indoor darkness is not an AMD treatment.
Exercise supports health and independence, adjusted for falls, cardiac limitations and vision. A person with central loss may need contrast markings, mobility instruction or a companion in unfamiliar environments.
Rehabilitation should not wait until legal blindness. Early training can address reading speed, glare, medication labels, cooking and device access while the person still has reserve and confidence.
Use bright, even task lighting without direct glare. Increase text size and weight, test reverse contrast, use line guides and text-to-speech, and organize frequently used items consistently. Contrast cutting boards, tactile labels and talking devices improve safety. A low-vision clinician can match magnification to working distance and field needs.
Driving decisions require more than a chart number. Contrast, scotoma location, glare recovery, cognition and local legal requirements matter. Report near misses honestly and consider a formal driving evaluation.
NRT at Netra Eye Institute cannot shrink GA, restore RPE or photoreceptors, change complement activity or replace retina injections. Any new distortion or sudden decline requires medical retinal assessment before rehabilitation.
After the retina is diagnosed and stable, a functional evaluation may map the relationship between the scotoma, fixation and daily tasks. Training can help a patient establish or use a preferred retinal locus, shift fixation away from a missing area, scan systematically and coordinate magnification with eye movements.
NRT may also address visual attention, binocular interference, contrast strategies and endurance. The goal is more effective use of available vision. Progress should be measured through reading rate, accuracy, search time or independence, not an unsupported claim that retinal tissue regenerated.
Care may involve retina specialists, low-vision optometrists, occupational therapists, orientation-and-mobility specialists and mental-health support. Learn about Netra Restoration Therapy, Netra Eye Institute’s approach and living well with low vision.
No. Many remain stable. Risk depends on drusen size and area, pigment changes, OCT features, fellow-eye status, age, smoking and other factors.
Not necessarily. Drusen can collapse as overlying RPE and photoreceptors become atrophic. OCT and autofluorescence show whether tissue was preserved.
No. GA is advanced nonexudative AMD with tissue loss; wet AMD involves macular neovascular leakage or bleeding. Both can occur in the same eye.
The lesion may spare the foveal center. Surrounding loss can still slow reading and reduce contrast. Acuity samples one small central task.
They are approved to slow average GA lesion growth, not restore lost retina. Individual benefit, burden and risk require retina-specialist discussion.
Many eligible patients continue it. A 2024 analysis suggests possible slowing toward the fovea for noncentral GA, but supplementation must be individualized and is not a replacement for approved therapy or monitoring.
No. NRT is rehabilitation for selected functional limitations after medical stabilization. It does not alter GA biology.
Dry AMD progression is neither harmless nor predetermined. Drusen and pigment change identify a vulnerable macular environment; some eyes remain stable, while others develop neovascular disease, geographic atrophy or both. Drusen may disappear as tissue deteriorates, and foveal sparing can hide serious reading and contrast loss behind relatively good acuity.
Serial multimodal imaging, stage-appropriate AREDS2, prompt response to new distortion and individualized discussion of approved GA injections form the medical plan. Rehabilitation, accessibility and NRT can help people use remaining vision more effectively, but they do not stop the biological progression.
Medical Disclaimer: This article is for general education and is not medical advice, diagnosis or treatment. New distortion, a central blank area or sudden visual decline requires prompt retinal evaluation. AREDS2, complement-inhibitor injections and monitoring must be individualized by licensed eye-care professionals. NRT cannot stop geographic atrophy and must never delay or replace dilation, OCT, injections or other established care.
